New Zealand markets closed
  • NZX 50

    11,102.84
    -70.53 (-0.63%)
     
  • NZD/USD

    0.6460
    -0.0018 (-0.28%)
     
  • NZD/EUR

    0.6045
    -0.0015 (-0.25%)
     
  • ALL ORDS

    7,353.40
    -38.30 (-0.52%)
     
  • ASX 200

    7,118.70
    -36.50 (-0.51%)
     
  • OIL

    110.95
    +0.62 (+0.56%)
     
  • GOLD

    1,843.60
    -2.70 (-0.15%)
     
  • NASDAQ

    11,943.93
    +174.09 (+1.48%)
     
  • FTSE

    7,522.75
    +38.40 (+0.51%)
     
  • Dow Jones

    32,120.28
    +191.66 (+0.60%)
     
  • DAX

    14,007.93
    +88.18 (+0.63%)
     
  • Hang Seng

    20,033.84
    -137.43 (-0.68%)
     
  • NIKKEI 225

    26,656.96
    -20.84 (-0.08%)
     
  • NZD/JPY

    82.2900
    -0.1010 (-0.12%)
     

World-Renowned Heart Failure Physicians To Feature Innovative Heart Failure Therapies at Technology and Heart Failure Therapeutics, February 1-2, 2022

·3-min read

SAN RAMON, Calif., January 28, 2022--(BUSINESS WIRE)--BioVentrix, Inc.:

WHAT:

Innovative therapeutic approaches for the left ventricle may slow progression or reverse congestive heart failure (CHF).

WHY:

  • Cardiomyopathy is a disease of the heart muscle that adversely affects the left ventricle, known to be the root cause of congestive heart failure

  • New, minimally invasive left ventricular (LV) restoration therapies have the potential to slow progression or reverse ischemic and idiopathic heart failure

  • Learn about Less Invasive Ventricular Enhancement (LIVE) through BioVentrix Revivent TC™ Transcatheter Ventricular Enhancement

  • Learn more about this technology and clinical trial results at THT

THERAPEUTIC TARGETS:

  • Ischemic and idiopathic heart failure

  • Cardiomyopathy

WHEN/WHERE:

February 1-2, 2022 (various times, see Presentations below)
Technology and Heart Failure Therapeutics (THT) Conference
New York Marriott Marquis Hotel
New York, NY

PRESENTATIONS:

World-renowned heart failure physicians will feature Less Invasive Ventricular Enhancement (LIVE) at THT in a dedicated breakfast symposium and a left ventricular remodeling for heart failure session with a focus on predictive indexes and prognostic measurements for left ventricular reshaping, short and long-term data outcomes, case reports, and trial updates.

  1. The Left Ventricle: Interventional Heart Failure’s Next Frontier (Breakfast Symposium)

    1. Date: Wednesday, February 2, 2022

    2. Time: 6:15-7:45 a.m. ET

    3. Location: New York Marriott Marquis, Julliard Complex, 5th Floor

    4. Panelists & Presenters: Dr. Jennifer Cowger (Henry Ford, USA), Dr. Gregg Stone (Mt. Sinai, USA), Prof. Stefan Anker (Charité University, Germany), Dr. Patrick Klein (St. Antonius Hospital, NL), Dr. Rishi Puri (Cleveland Clinic, USA), Dr. Ryan Tedford (MUSC, USA)

  2. Transcatheter Ventricular Remodeling for Heart Failure

    1. Date: Wednesday, February 2, 2022

    2. Time: 3:25-4:05 p.m. ET

    3. Location: New York Marriott Marquis, Broadway Theater, Westside Ballroom, 5th Floor

    4. Presenter: Dr. Jerry Estep (Cleveland Clinic, USA)

  3. Mid-Term Outcome of Hybrid Transcatheter and Minimally Invasive Left Ventricular Reconstruction for the Treatment of Ischemic Heart Failure (Poster Presentation)

    1. Date: Wednesday, February 2, 2022

    2. Time: Intermissions

    3. Location: New York Marriott Marquis, Broadway Theater, Westside Ballroom, 5th Floor

    4. Presenters: Dr. Patrick Klein & Dr. Romy Hegeman (St. Antonius Hospital, NL)

ABOUT BIOVENTRIX:

BioVentrix, Inc. is a privately held medical device company headquartered in San Ramon, California. The Company’s mission is to treat patients with congestive heart failure caused by dilated cardiomyopathy. BioVentrix’s Revivent TC™ system received the CE Mark and is currently pending FDA approval in the United States.

ABOUT CARDIOMYOPATHY:

Cardiomyopathy represents a collection of diverse conditions of the heart muscle. These diseases have many causes, and symptoms that affect people of all ages and races. When cardiomyopathy occurs, the normal muscle in the heart can thicken, stiffen, thin out, or fill with substances the body produces that do not belong in the heart. As a result, the heart muscle’s ability to pump blood is reduced, which can lead to an irregular heart rhythm, the backup of blood into the lungs or rest of the body, and death. Cardiomyopathy can be acquired—developed because of another disease, condition, or factor—or inherited. The cause is not always known.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220128005038/en/

Contacts

MEDIA CONTACT
Nicholas Corso, Director of Marketing
(760) 500-1595
ncorso@bioventrix.com

BIOVENTRIX AT THT
Jim Dillon, President & CEO
(781) 801-0507
jdillon@bioventrix.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting